BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

Biomarin Up After Q3 Earnings: Here’s Everything You Need to Know

BioMarin Pharmaceutical (Nasdaq: BMRN) missed both revenue and earnings estimates in the third quarter, and yet, shares are up 1% in after-hours trading. Let’s dig into what happened in the company’s third quarter and what it says about the future for the company.  The stock closed at $52.67, erasing earlier gains and reflecting investor disappointment despite some bright spots in the company’s pipeline and cash position. Miss Overshadows Strong…

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

Raises Full-year 2025 Total Revenues Guidance at the Midpoint; Reaffirms VOXZOGO Full-year Outlook